Fig. 4: Chemotherapy-free survival.
Chemotherapy-free survival (with 95% CIs) amongst the real-world cohort that received abemaciclib plus fulvestrant for the treatment of advanced HR+/HER2− breast cancer (N = 876).
Fig. 4: Chemotherapy-free survival. | British Journal of Cancer
